Biography
Gal Bitan got his PhD in organic chemistry from the Hebrew University of Jerusalem, Israel. Dr. Bitan’s graduate work on unnatural amino acids and non-conventional peptide cyclization methodologies led him to postdoctoral studies on the structural biology of ligand-receptor systems including integrins and G protein-coupled receptors at Clark University, Worcester, MA and Beth Israel-Deaconess Medical Center/Harvard Medical School, Boston, MA. Dr. Bitan then moved on to tackle the problem of protein misfolding and aggregation, which is involved in over 30 devastating diseases, such as Alzheimer’s disease, Parkinson’s disease, prion diseases (e.g., Mad Cow disease), amyotrophic lateral sclerosis (Lou Gherig’s disease), and type II diabetes. Working at Brigham and Women’s Hospital/Harvard Medical School, Boston, MA, Dr. Bitan has made fundamental contributions to the study of early events in the pathologic cascades that cause Alzheimer’s disease. In Alzheimer’s disease, the amyloid ß-protein (Aß) self-associates to form a variety of oligomeric and polymeric structures with potent neurotoxic activities. In particular, Aß oligomers have been implicated as the probable cause of Alzheimer’s disease. Dr. Bitan introduced the use of novel photochemical protein cross-linking techniques for investigation of Aß assembly and discovered one of the earliest oligomers in the assembly cascade, the paranucleus. In 2004, Dr. Bitan joined UCLA where he is currently a Professor of Neurology. His research program is focused on translational science geared at developing novel, mechanism-based diagnostic and therapeutic tools for neurodegenerative diseases, including Alzheimer’s disease and other tauopathies, Parkinson’s disease, multiple system atrophy, and amyotrophic lateral sclerosis.
Biography
Epilepsy, basic mechanisms
View a up-to-date publication list: https://scholar.google.com/citations?hl=en&user=WcurRvgAAAAJ&view_op=list_works&sortby=pubdate
Biography
Jeff Bronstein received his bachelor’s degree from the University of California, Berkeley and M.D. and Ph.D. from UCLA as a recipient of the Medical Scientist Training Program Award. He completed a residency in Neurology and fellowship training in Movement Disorders at UCLA. Dr. Bronstein also completed a postdoctoral fellowship in molecular biology before being appointed an Assistant Professor of Neurology. He was later appointed Director of the Movement Disorders Program at UCLA. His interests and expertise include the management of Parkinson’s disease (PD) and other movement disorders, surgical treatment of PD, and developing new therapies for patients. Dr. Bronstein was recently awarded one of 6 National Parkinson’s Disease Centers at the Veterans Administration Medical Center with the goal of furthering research, education and clinical care in the Southwest US. His laboratory studies the cause of PD using cell models and a newly developed zebrafish model. His work supported by the NIH and private foundations. Dr. Bronstein also directs clinical trials in order to develop new therapies for PD that include transplantation and deep brain stimulation. He has received several awards and is widely published in the field.